Abstract #0235

Differential imaging biomarker response to sunitinib across tumor histologies in a prospective trial of brain metastases

Caroline Chung¹, Brandon Driscoll¹, Warren Foltz¹, Cynthia Menard¹, David Jaffray¹, and Catherine Coolens¹

¹Princess Margaret Cancer Centre, Toronto, ON, Canada

Our preclinical study of sunitinib (SU) in combination with conformal large single fraction radiation in an orthotopic murine brain tumor model, discovered that changes in apparent diffusion coefficient (ADC), AUC and Ktrans were promising imaging biomarkers that could predict response to SU as well as combined SU and radiation. Based on our preclinical findings, we designed a prospective phase I trial of SU and radiosurgery (SRS) for brain metastases that incorporated translational investigation of these imaging biomarkers. Here we summarize our discovery of differential ADC and AUC responses to sunitinib between renal cell cancer and other histology brain metastases.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.